GPX2 and neoplasm: Consistent with the A549-derived results, tumor growth measurement revealed that GPX2 silencing potentiated gefitinib-induced tumor growth inhibition in HCC827-GR-derived nude mice (Fig. S2A), with tumor sizes and endpoint weights demonstrating a synergistic effect of GPX2 knockdown plus gefitinib (Fig. S2B–C).